Marcello C. Laurenti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcello C. Laurenti has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Vella
Mayo Clinic
15 shared publications - Chiara Dalla Man
Department of Information Engineering, University of Padova, Padova, Italy
14 shared publications - Claudio Cobelli
University of Padova, Padova, Italy
9 shared publications - Aoife Maria Egan
Division of Endocrinology, Metabolism, and Diabetes, Mayo Clinic, Rochester, Minnesota, USA
5 shared publications - Aleksey V. Matveyenko
Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA
4 shared publications J.D. Adams
Rochester, MN, Padova, Italy
4 shared publications
Latest Publications
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 330  (4) , E530-E539
Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion
In this study, we propose two new mathematical models able to quantify glucagon secretion during a graded glucose infusion, in the presence and absence of amino acids. The models provide an index of α-cell responsivity, G 50 , i.e., the glucose increase required to suppress glucose secretion rate (GSR) by 50%. Results show that the presence of amino acids reduced α-cell responsivity to glucose.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 330  (4) , E530-E539
Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion
In this study, we propose two new mathematical models able to quantify glucagon secretion during a graded glucose infusion, in the presence and absence of amino acids. The models provide an index of α-cell responsivity, G 50 , i.e., the glucose increase required to suppress glucose secretion rate (GSR) by 50%. Results show that the presence of amino acids reduced α-cell responsivity to glucose.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 329  (6) , R894-R904
Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions
The model can be used to quantify hepatic glucagon and insulin sensitivity, accounting also for glucagon evanescence over time. The ability to quantify glucagon effects on postprandial glucose metabolism will further our understanding of its role in the onset and progression of type 2 diabetes. These findings can also be used in the design of novel glucagon-based therapies where accurate modeling of glucagon action is required to meet efficacy and safety standards.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 329  (6) , R894-R904
Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions
The model can be used to quantify hepatic glucagon and insulin sensitivity, accounting also for glucagon evanescence over time. The ability to quantify glucagon effects on postprandial glucose metabolism will further our understanding of its role in the onset and progression of type 2 diabetes. These findings can also be used in the design of novel glucagon-based therapies where accurate modeling of glucagon action is required to meet efficacy and safety standards.
- Open Access
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 328  (1) , E62-E68
Enhanced quantification of α-cell suppression by hyperglycemia using a high-sensitivity glucagon assay
We describe a method that lowers the limit of quantification of a glucagon immunoassay thereby enhancing the ability to differentiate between normal and abnormal α-cell responsiveness to glucagon.
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 328  (1) , E62-E68
Open AccessEnhanced quantification of α-cell suppression by hyperglycemia using a high-sensitivity glucagon assay
We describe a method that lowers the limit of quantification of a glucagon immunoassay thereby enhancing the ability to differentiate between normal and abnormal α-cell responsiveness to glucagon.
- Open Access
- 15 November 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133  (22)
Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans
BACKGROUND. Proglucagon can be processed to glucagon-like peptide1 (GLP-1) within the islet, but its contribution to islet function in humans remains unknown. We sought to understand whether pancreatic GLP-1 alters islet function in humans and whether this is affected by type 2 diabetes. METHODS. We therefore studied individuals with and without type 2 diabetes on two occasions in random order. On one occasion, exendin 9-39, a competitive antagonist of the GLP-1 Receptor (GLP1R), was infused, while on the other, saline was infused. The tracer dilution technique ([3-3H] glucose) was used to measure glucose turnover during fasting and during a hyperglycemic clamp. RESULTS. Exendin 9-39 increased fasting glucose concentrations; fasting islet hormone concentrations were unchanged, but inappropriate for the higher fasting glucose observed. In people with type 2 diabetes, fasting glucagon concentrations were markedly elevated and persisted despite hyperglycemia. This impaired suppression of endogenous glucose production by hyperglycemia. CONCLUSION. These data show that GLP1R blockade impairs islet function, implying that intra-islet GLP1R activation alters islet responses to glucose and does so to a greater degree in people with type 2 diabetes. TRIAL REGISTRATION. This study was registered at ClinicalTrials.gov NCT04466618. FUNDING. The study was primarily funded by NIH NIDDK DK126206. AV is supported by DK78646, DK116231 and DK126206. CDM was supported by MIUR (Italian Minister for Education) under the initiative “Departments of Excellence” (Law 232/2016).
- 15 November 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133  (22)
Open AccessGlucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans
BACKGROUND. Proglucagon can be processed to glucagon-like peptide1 (GLP-1) within the islet, but its contribution to islet function in humans remains unknown. We sought to understand whether pancreatic GLP-1 alters islet function in humans and whether this is affected by type 2 diabetes. METHODS. We therefore studied individuals with and without type 2 diabetes on two occasions in random order. On one occasion, exendin 9-39, a competitive antagonist of the GLP-1 Receptor (GLP1R), was infused, while on the other, saline was infused. The tracer dilution technique ([3-3H] glucose) was used to measure glucose turnover during fasting and during a hyperglycemic clamp. RESULTS. Exendin 9-39 increased fasting glucose concentrations; fasting islet hormone concentrations were unchanged, but inappropriate for the higher fasting glucose observed. In people with type 2 diabetes, fasting glucagon concentrations were markedly elevated and persisted despite hyperglycemia. This impaired suppression of endogenous glucose production by hyperglycemia. CONCLUSION. These data show that GLP1R blockade impairs islet function, implying that intra-islet GLP1R activation alters islet responses to glucose and does so to a greater degree in people with type 2 diabetes. TRIAL REGISTRATION. This study was registered at ClinicalTrials.gov NCT04466618. FUNDING. The study was primarily funded by NIH NIDDK DK126206. AV is supported by DK78646, DK116231 and DK126206. CDM was supported by MIUR (Italian Minister for Education) under the initiative “Departments of Excellence” (Law 232/2016).
- 27 September 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109  (2) , e596-e601
Suppression of Endogenous Insulin Secretion by Euglycemic Hyperinsulinemia
Context: The impact of insulin, particularly exogenous hyperinsulinemia, on insulin secretion in humans is debated. Objective: We assessed the effects of exogenous hyperinsulinemia on insulin secretion and whether the response is altered in insulin resistance associated with obesity. Methods: Insulin secretion rates (ISRs) during euglycemic hyperinsulinemic clamp studies (52 volunteers) were calculated using a model that employs plasma C-peptide concentrations. One study involved a 2-step insulin clamp and the other study was a single step insulin clamp. For both studies the goal was to achieve plasma glucose concentrations of 95 mg/dL during the clamp irrespective of fasting glucose concentrations. The percent change in ISR from fasting to the end of the insulin clamp interval was the main outcome. Linear regression and analysis of covariance were used to test for the effects of insulin on ISR and to test for group differences. Results: ISR was greater in obese volunteers (P < .001) under fasting and hyperinsulinemic clamp conditions. The change in plasma glucose from baseline to the end of the insulin clamp interval was highly correlated with the change in ISR (r = 0.61, P < .001). From baseline to the end of the clamp we observed a 27% (SD 20) suppression of ISR. The participants who underwent a 2-step insulin clamp had greater suppression of ISR during the second step than the first step (P < .001). The proportional suppression of ISR during euglycemic hyperinsulinemia was not different between nonobese and obese groups (P = .19). Conclusion: Hyperinsulinemia suppresses endogenous insulin secretion and the relative change in insulin secretion produced by exogenous insulin did not differ between nonobese and obese people.
- 27 September 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109  (2) , e596-e601
Suppression of Endogenous Insulin Secretion by Euglycemic Hyperinsulinemia
Context: The impact of insulin, particularly exogenous hyperinsulinemia, on insulin secretion in humans is debated. Objective: We assessed the effects of exogenous hyperinsulinemia on insulin secretion and whether the response is altered in insulin resistance associated with obesity. Methods: Insulin secretion rates (ISRs) during euglycemic hyperinsulinemic clamp studies (52 volunteers) were calculated using a model that employs plasma C-peptide concentrations. One study involved a 2-step insulin clamp and the other study was a single step insulin clamp. For both studies the goal was to achieve plasma glucose concentrations of 95 mg/dL during the clamp irrespective of fasting glucose concentrations. The percent change in ISR from fasting to the end of the insulin clamp interval was the main outcome. Linear regression and analysis of covariance were used to test for the effects of insulin on ISR and to test for group differences. Results: ISR was greater in obese volunteers (P < .001) under fasting and hyperinsulinemic clamp conditions. The change in plasma glucose from baseline to the end of the insulin clamp interval was highly correlated with the change in ISR (r = 0.61, P < .001). From baseline to the end of the clamp we observed a 27% (SD 20) suppression of ISR. The participants who underwent a 2-step insulin clamp had greater suppression of ISR during the second step than the first step (P < .001). The proportional suppression of ISR during euglycemic hyperinsulinemia was not different between nonobese and obese groups (P = .19). Conclusion: Hyperinsulinemia suppresses endogenous insulin secretion and the relative change in insulin secretion produced by exogenous insulin did not differ between nonobese and obese people.
- 1 August 2023
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 325  (2) , E119-E131
Effects of acute changes in fasting glucose and free fatty acid concentrations on indices of β-cell function and glucose metabolism in subjects without diabetes
This experiment studied the effect of changes in overnight concentrations of free fatty acids (FFAs) and glucose on β-cell function and glucose metabolism. In response to elevation of these metabolites, the dynamic component of the β-cell response to glucose was impaired. This suggests that in health overnight hyperglycemia and FFA elevation can deplete preformed insulin granules in the β-cell.
- 1 August 2023
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 325  (2) , E119-E131
Effects of acute changes in fasting glucose and free fatty acid concentrations on indices of β-cell function and glucose metabolism in subjects without diabetes
This experiment studied the effect of changes in overnight concentrations of free fatty acids (FFAs) and glucose on β-cell function and glucose metabolism. In response to elevation of these metabolites, the dynamic component of the β-cell response to glucose was impaired. This suggests that in health overnight hyperglycemia and FFA elevation can deplete preformed insulin granules in the β-cell.
- Open Access
- 29 March 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 70  (9) , 2733-2740
Nonlinear Mixed Effects Modeling of Glucagon Kinetics in Healthy Subjects
Objective : To date, the lack of a model of glucagon kinetics precluded the possibility of estimating and studying glucagon secretion in vivo , e.g., using deconvolution, as done for other hormones like insulin and C-peptide. Here, we used a nonlinear mixed effects technique to develop a robust population model of glucagon kinetics, able to describe both the typical population kinetics (TPK) and the between-subject variability (BSV), and relate this last to easily measurable subject characteristics. Methods : Thirty-four models of increasing complexity (variably including covariates and correlations among random effects) were identified on glucagon profiles obtained from 53 healthy subjects, who received a constant infusion of somatostatin to suppress endogenous glucagon production, followed by a continuous infusion of glucagon (65 ng/kg/min). Model selection was performed based on its ability to fit the data, provide precise parameter estimates, and parsimony criteria. Results : A two-compartment model was the most parsimonious. The model was able to accurately describe both the TPK and the BSV of model parameters as function of body mass and body surface area. Parameters were precisely estimated, with central volume of distribution V1 = 5.46 L and peripheral volume of distribution V2 = 5.51 L. The introduction of covariates resulted in a significant shrinkage of the unexplained BSV and considerably improved the model fit. Conclusion : We developed a robust population model of glucagon kinetics. Significance : This model provides a deeper understanding of glucagon kinetics and is usable to estimate glucagon secretion in vivo by deconvolution of plasma glucagon concentration data.
- 29 March 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 70  (9) , 2733-2740
Open AccessNonlinear Mixed Effects Modeling of Glucagon Kinetics in Healthy Subjects
Objective : To date, the lack of a model of glucagon kinetics precluded the possibility of estimating and studying glucagon secretion in vivo , e.g., using deconvolution, as done for other hormones like insulin and C-peptide. Here, we used a nonlinear mixed effects technique to develop a robust population model of glucagon kinetics, able to describe both the typical population kinetics (TPK) and the between-subject variability (BSV), and relate this last to easily measurable subject characteristics. Methods : Thirty-four models of increasing complexity (variably including covariates and correlations among random effects) were identified on glucagon profiles obtained from 53 healthy subjects, who received a constant infusion of somatostatin to suppress endogenous glucagon production, followed by a continuous infusion of glucagon (65 ng/kg/min). Model selection was performed based on its ability to fit the data, provide precise parameter estimates, and parsimony criteria. Results : A two-compartment model was the most parsimonious. The model was able to accurately describe both the TPK and the BSV of model parameters as function of body mass and body surface area. Parameters were precisely estimated, with central volume of distribution V1 = 5.46 L and peripheral volume of distribution V2 = 5.51 L. The introduction of covariates resulted in a significant shrinkage of the unexplained BSV and considerably improved the model fit. Conclusion : We developed a robust population model of glucagon kinetics. Significance : This model provides a deeper understanding of glucagon kinetics and is usable to estimate glucagon secretion in vivo by deconvolution of plasma glucagon concentration data.
- 18 October 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 77
Abnormalities of glucagon suppression and stimulation of insulin secretion in response to rising glucose concentrations interact in impaired fasting glucose and impaired glucose tolerance
Impaired glucagon suppression is an overlooked contributor to the transition of prediabetes to type 2 diabetes. We used Graded Glucose Infusion (GGI) to examine the relationship of ISR and Glucagon Secretion Rate (GSR) with rising glucose. We studied 39 non-diabetic, weight-stable individuals (53±2 yrs, 30±1 Kg/M2) categorized by fasting and glucose tolerance status following a 75g OGTT at the time of screening. After an overnight fast, at 07:00 a variable insulin infusion was used to maintain glucose at ~4.4 mmol/l (until 08:30) enabling the subsequent measurement of ISR and GSR in response to rising glucose concentrations. At 09:00 GGI commenced, starting at 1 mg/kg/min and doubling every 60 min until 13:00. GSR and ISR were calculated by nonparametric deconvolution from plasma concentrations of glucagon and c-peptide respectively. GSR exhibited an exponential relationship with glucose, that could be characterized by τ – the change in glucose necessary to suppress GSR by 50%. τ was increased in people with impaired fasting glucose (IFG) compared to those with normal fasting glucose (NFG) regardless of the presence or absence of impaired or normal glucose tolerance (IGT or NGT – 1.4±0.2 vs. 1.5±0.2 vs. 2.0±0.2 vs. 2.5±0.3 mmol/l, P P <0.01, NFG/NGT vs. NFG/IGT vs. IFG/NGT vs. IFG/IGT respectively). These data show that in non-diabetic humans, both α-cell and β-cell dysfunction contribute differentially to the subtypes of prediabetes. This may have implications for the design of targeted interventions for prediabetes.
- 18 October 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 77
Abnormalities of glucagon suppression and stimulation of insulin secretion in response to rising glucose concentrations interact in impaired fasting glucose and impaired glucose tolerance
Impaired glucagon suppression is an overlooked contributor to the transition of prediabetes to type 2 diabetes. We used Graded Glucose Infusion (GGI) to examine the relationship of ISR and Glucagon Secretion Rate (GSR) with rising glucose. We studied 39 non-diabetic, weight-stable individuals (53±2 yrs, 30±1 Kg/M2) categorized by fasting and glucose tolerance status following a 75g OGTT at the time of screening. After an overnight fast, at 07:00 a variable insulin infusion was used to maintain glucose at ~4.4 mmol/l (until 08:30) enabling the subsequent measurement of ISR and GSR in response to rising glucose concentrations. At 09:00 GGI commenced, starting at 1 mg/kg/min and doubling every 60 min until 13:00. GSR and ISR were calculated by nonparametric deconvolution from plasma concentrations of glucagon and c-peptide respectively. GSR exhibited an exponential relationship with glucose, that could be characterized by τ – the change in glucose necessary to suppress GSR by 50%. τ was increased in people with impaired fasting glucose (IFG) compared to those with normal fasting glucose (NFG) regardless of the presence or absence of impaired or normal glucose tolerance (IGT or NGT – 1.4±0.2 vs. 1.5±0.2 vs. 2.0±0.2 vs. 2.5±0.3 mmol/l, P P <0.01, NFG/NGT vs. NFG/IGT vs. IFG/NGT vs. IFG/IGT respectively). These data show that in non-diabetic humans, both α-cell and β-cell dysfunction contribute differentially to the subtypes of prediabetes. This may have implications for the design of targeted interventions for prediabetes.
- Open Access
- 22 June 2021
- Published by MDPI AG in Metabolites
- Vol. 11  (7) , 409
Measurement of Pulsatile Insulin Secretion: Rationale and Methodology
Pancreatic β-cells are responsible for the synthesis and exocytosis of insulin in response to an increase in circulating glucose. Insulin secretion occurs in a pulsatile manner, with oscillatory pulses superimposed on a basal secretion rate. Insulin pulses are a marker of β-cell health, and secretory parameters, such as pulse amplitude, time interval and frequency distribution, are impaired in obesity, aging and type 2 diabetes. In this review, we detail the mechanisms of insulin production and β-cell synchronization that regulate pulsatile insulin secretion, and we discuss the challenges to consider when measuring fast oscillatory secretion in vivo. These include the anatomical difficulties of measuring portal vein insulin noninvasively in humans before the hormone is extracted by the liver and quickly removed from the circulation. Peripheral concentrations of insulin or C-peptide, a peptide cosecreted with insulin, can be used to estimate their secretion profile, but mathematical deconvolution is required. Parametric and nonparametric approaches to the deconvolution problem are evaluated, alongside the assumptions and trade-offs required for their application in the quantification of unknown insulin secretory rates from known peripheral concentrations. Finally, we discuss the therapeutical implication of targeting impaired pulsatile secretion and its diagnostic value as an early indicator of β-cell stress.
- 22 June 2021
- Published by MDPI AG in Metabolites
- Vol. 11  (7) , 409
Open AccessMeasurement of Pulsatile Insulin Secretion: Rationale and Methodology
Pancreatic β-cells are responsible for the synthesis and exocytosis of insulin in response to an increase in circulating glucose. Insulin secretion occurs in a pulsatile manner, with oscillatory pulses superimposed on a basal secretion rate. Insulin pulses are a marker of β-cell health, and secretory parameters, such as pulse amplitude, time interval and frequency distribution, are impaired in obesity, aging and type 2 diabetes. In this review, we detail the mechanisms of insulin production and β-cell synchronization that regulate pulsatile insulin secretion, and we discuss the challenges to consider when measuring fast oscillatory secretion in vivo. These include the anatomical difficulties of measuring portal vein insulin noninvasively in humans before the hormone is extracted by the liver and quickly removed from the circulation. Peripheral concentrations of insulin or C-peptide, a peptide cosecreted with insulin, can be used to estimate their secretion profile, but mathematical deconvolution is required. Parametric and nonparametric approaches to the deconvolution problem are evaluated, alongside the assumptions and trade-offs required for their application in the quantification of unknown insulin secretory rates from known peripheral concentrations. Finally, we discuss the therapeutical implication of targeting impaired pulsatile secretion and its diagnostic value as an early indicator of β-cell stress.
- Open Access
- 9 April 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5  (7)
Diabetes-associated genetic variation in TCF7L2 alters pulsatile insulin secretion in humans
BACKGROUND: Metabolic disorders such as type 2 diabetes have been associated with a decrease in insulin pulse frequency and amplitude. We hypothesized that the T allele at rs7903146 in TCF7L2, previously associated with β cell dysfunction, would be associated with changes in these insulin pulse characteristics. METHODS: Twenty-nine nondiabetic subjects (age 46 ± 2, BMI 28 ± 1 kg/m 2 ) participated in this study. Of these, 16 were homozygous for the C allele at rs7903146 and 13 were homozygous for the T allele. Deconvolution of peripheral C-peptide concentrations allowed the reconstruction of portal insulin secretion over time. These data were used for subsequent analyses. Pulse orderliness was assessed by approximate entropy (ApEn), and the dispersion of insulin pulses was measured by a frequency dispersion index (FDI) after a Fast Fourier Transform (FFT) of individual insulin secretion rates. RESULTS: During fasting conditions, the CC genotype group exhibited decreased pulse disorderliness compared with the TT genotype group (1.10 ± 0.03 vs. 1.19 ± 0.04, P = 0.03). FDI decreased in response to hyperglycemia in the CC genotype group, perhaps reflecting less entrainment of insulin secretion during fasting. CONCLUSION: Diabetes-associated variation in TCF7L2 is associated with decreased orderliness and pulse dispersion, unchanged by hyperglycemia. Quantification of ApEn and FDI could represent novel markers of β cell health. FUNDING: This work was funded by US NIH (DK78646, DK116231), University of Padova research grant CPDA145405, and Mayo Clinic General Clinical Research Center (UL1 TR000135).
- 9 April 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5  (7)
Open AccessDiabetes-associated genetic variation in TCF7L2 alters pulsatile insulin secretion in humans
BACKGROUND: Metabolic disorders such as type 2 diabetes have been associated with a decrease in insulin pulse frequency and amplitude. We hypothesized that the T allele at rs7903146 in TCF7L2, previously associated with β cell dysfunction, would be associated with changes in these insulin pulse characteristics. METHODS: Twenty-nine nondiabetic subjects (age 46 ± 2, BMI 28 ± 1 kg/m 2 ) participated in this study. Of these, 16 were homozygous for the C allele at rs7903146 and 13 were homozygous for the T allele. Deconvolution of peripheral C-peptide concentrations allowed the reconstruction of portal insulin secretion over time. These data were used for subsequent analyses. Pulse orderliness was assessed by approximate entropy (ApEn), and the dispersion of insulin pulses was measured by a frequency dispersion index (FDI) after a Fast Fourier Transform (FFT) of individual insulin secretion rates. RESULTS: During fasting conditions, the CC genotype group exhibited decreased pulse disorderliness compared with the TT genotype group (1.10 ± 0.03 vs. 1.19 ± 0.04, P = 0.03). FDI decreased in response to hyperglycemia in the CC genotype group, perhaps reflecting less entrainment of insulin secretion during fasting. CONCLUSION: Diabetes-associated variation in TCF7L2 is associated with decreased orderliness and pulse dispersion, unchanged by hyperglycemia. Quantification of ApEn and FDI could represent novel markers of β cell health. FUNDING: This work was funded by US NIH (DK78646, DK116231), University of Padova research grant CPDA145405, and Mayo Clinic General Clinical Research Center (UL1 TR000135).